Last reviewed · How we verify
bupropion extra long (XL)
Bupropion XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse.
Bupropion XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as adjunctive therapy).
At a glance
| Generic name | bupropion extra long (XL) |
|---|---|
| Also known as | Wellbutrin extra long (XL) |
| Sponsor | New York State Psychiatric Institute |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET), dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The XL formulation provides extended-release delivery for once-daily dosing, maintaining therapeutic levels throughout the day.
Approved indications
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation (as adjunctive therapy)
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Constipation
- Seizures (dose-dependent)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupropion extra long (XL) CI brief — competitive landscape report
- bupropion extra long (XL) updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI